Sugi Predict

Sugi Predict / Compounds / SCHEMBL3000663

SCHEMBL3000663

SCHEMBL3000663

COC(=O)[C@]1(C)CCCN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ GRIN2B Q13224 1/20 0.40
▸ GRIN2C Q14957 1/20 0.40
▸ JAK3 P52333 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CTSK P43235 1/20 0.36
▸ EPHX1 P07099 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ EPHX2 P34913 1/20 0.34
▸ HSD11B1 P28845 1/20 0.32
▸ NR1H2 P55055 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3000664 1.00 GRIN2B (0.40) GRIN2BGRIN2CJAK3USP2SMN1; SMN2
SCHEMBL10039817 1.00 GRIN2B (0.40) GRIN2BGRIN2CJAK3USP2SMN1; SMN2
SCHEMBL24999580 0.95 JAK3 (0.39) GRIN2BGRIN2CJAK3USP2SMN1; SMN2
SCHEMBL3267126 0.90 GRIN2B (0.41) GRIN2BGRIN2CJAK3USP2SMN1; SMN2
SCHEMBL11954515 0.90 USP2 (0.38) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL11954522 0.90 USP2 (0.38) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL31078891 0.90 USP2 (0.38) GRIN2BGRIN2CUSP2SMN1; SMN2CTSK
SCHEMBL15125135 0.86 GRIN2B (0.46) GRIN2BGRIN2CJAK3USP2SMN1; SMN2
SCHEMBL14234512 0.86 GRIN2B (0.46) GRIN2BGRIN2CJAK3USP2SMN1; SMN2
SCHEMBL6632443 0.86 GRIN2B (0.46) GRIN2BGRIN2CJAK3USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743175-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Aconcagua Bio, Inc. (US) 2026-05-20 — — EP disclosed
US-20250051355-A1 COMPOUNDS, COMPOSITIONS, AND METHODS ACONCAGUA BIO, INC. 2025-02-13 — — US disclosed
WO-2025015269-A1 COMPOUNDS, COMPOSITIONS, AND METHODS ACONCAGUA BIO, INC. (US) 2025-01-16 — — WO disclosed
EP-3911631-B1 NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES ZYDUS LIFESCIENCES LTD (IN) 2024-12-18 — — EP disclosed
US-12084416-B2 Substituted sulfonylurea derivatives ZYDUS LIFESCIENCES LIMITED (IN) 2024-09-10 — — US disclosed
US-20220169605-A1 NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES ZYDUS LIFESCIENCES LIMITED (IN) 2022-06-02 — — US disclosed
CN-105164117-B Dipeptides and tripeptide epoxy ketone protease inhibitors 欧尼斯治疗公司 2019-02-01 — — CN disclosed
US-8933116-B2 Gamma secretase inhibitors MERCK SHARP & DOHME CORP. (US) 2015-01-13 — — US disclosed
US-20140018342-A1 GAMMA SECRETASE INHIBITORS MERCK SHARP & DOHME LLC 2014-01-16 — — US disclosed
US-8415340-B2 Triazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-09 — — US disclosed
US-20100197654-A1 TRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-08-05 — — US disclosed
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 — — US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 — — US disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 — — EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 — — US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 — — US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 — — US disclosed
CN-1391473-A VLA-4 inhibitor compounds DAIICHI SEIYAKU CO (JP) 2003-01-15 — — CN disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 — — EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169605-A1 NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES NOD1, NLRP3, IL1R1 GRIN2B 3149/4885GRIN2C 3578/4885JAK3 2322/4885
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 GRIN2B 3811/4885GRIN2C 4455/4885JAK3 1382/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 GRIN2B 3759/4885GRIN2C 4378/4885JAK3 1496/4885
US-12084416-B2 Substituted sulfonylurea derivatives NOD1, NLRP3, IL1R1 GRIN2B 3239/4885GRIN2C 3583/4885JAK3 2174/4885
US-20100197654-A1 TRIAZINE KINASE INHIBITORS ABL1, STK25, FLT3 GRIN2B 2876/4885GRIN2C 2431/4885JAK3 62/4885
US-20140018342-A1 GAMMA SECRETASE INHIBITORS BACE1, BACE2, PSEN1 GRIN2B 315/4885GRIN2C 494/4885JAK3 4374/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 GRIN2B 3900/4885GRIN2C 4510/4885JAK3 1565/4885
US-20250051355-A1 COMPOUNDS, COMPOSITIONS, AND METHODS IAPP, GIPR, GPR119 GRIN2B 1277/4885GRIN2C 1060/4885JAK3 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.